John Liljenquist
Endocrinology, Diabetes & Metabolism · Idaho Falls, IDNPI 1619977600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 30.1% of the total. Reporting peaked in 2019 at $271 and has fallen 88.7% since, to $31 in 2025.
Across 33 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$145
- Novo Nordisk$78
- Boehringer Ingelheim$72
- Tandem Diabetes Care, Inc.$45
- Teva Pharmaceuticals USA, Inc.$41
- Lilly USA, LLC$32
- plus $68 from 4 others
Across 20 payments — averaging $27,652 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$553K
What the payments were for
- Food & beverage$44893%
- Education$327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $145 |
| Novo Nordisk | 4 | $78 |
| Boehringer Ingelheim | 5 | $72 |
| Tandem Diabetes Care, Inc. | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Lilly USA, LLC | 2 | $32 |
| Medtronic | 2 | $25 |
| Radius Health, Inc. | 1 | $18 |
| Boston Scientific | 1 | $14 |
| Abbott | 1 | $11 |
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $46,196 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,930 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,724 |
| Clonazepam | 13 | $453 |
| Metformin Hcl ErMetformin Hcl | 25 | $428 |
| Potassium Chloride | 16 | $291 |
| Atorvastatin Calcium | 23 | $203 |
| Levothyroxine Sodium | 29 | $186 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $147 |
| Pioglitazone Hcl | 12 | $55 |
| Hydrochlorothiazide | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $32 | $46,19646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Idaho Falls
- David LiljenquistIdaho Falls$9K
- Carl VanceIdaho Falls$729
- Robert EnnisMeridian$69K
- Theodore RooseveltBoise$65K
- Julie FooteBoise$8K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Shanaz SikderBoise$3K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.